Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dermatological evaluation of HB22
RBR-3rgpwgNot yet recruiting
- Sponsor
- Infinant Health
- Start
- Sep 2022
- Countries
- 1
01
Overview
Open-label, single-arm trial in photodermatoses, sponsored by Infinant Health. Primary endpoints: Dermal photoirritation response, Dermal photosensitization induction response and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Conditions
photodermatoses
Beyond the preview
Go deeper on RBR-3rgpwg.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3rgpwg.